FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Petra Steindl-Munda

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Hepacivirus

Procedures

Drug Therapy, Combination

Concepts & Ideas

Physiology

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Albert Friedrich Stättermayer; Petra Steindl-Munda; Michael Trauner; Fritz Wrba; Harald Hofer; Michael Krebs; Karoline Rutter; Thomas-Matthias Scherzer; Andreas Stadlmayr; Sandra Beinhardt; Christian Datz; Peter Ferenci
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.
Thomas-Matthias Scherzer; Albert Friedrich Stättermayer; Rudolf Stauber; Petra Steindl-Munda; Michael Strasser; Christian Datz; Emina Dulic-Lakovic; Harald Hofer; Hermann Laferl; Andreas Maieron; Peter Ferenci
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
Harald Hofer; C Mueller; S Neumueller-Guber; T-M Scherzer; K Staufer; Petra Steindl-Munda; F Wrba; I Aydin; Peter Ferenci
Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Petra Steindl-Munda (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Albert Friedrich Stättermayer; Petra Steindl-Munda; Michael Trauner; Fritz Wrba; Harald Hofer; Michael Krebs; Karoline Rutter; Thomas-Matthias Scherzer; Andreas Stadlmayr; Sandra Beinhardt; Christian Datz; Peter Ferenci
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.
Journal of hepatology 2012;57(3):492-8.
2011: Thomas-Matthias Scherzer; Albert Friedrich Stättermayer; Rudolf Stauber; Petra Steindl-Munda; Michael Strasser; Christian Datz; Emina Dulic-Lakovic; Harald Hofer; Hermann Laferl; Andreas Maieron; Peter Ferenci
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
Hepatology (Baltimore, Md.) 2011;54(5):1518-26.
2011: Harald Hofer; C Mueller; S Neumueller-Guber; T-M Scherzer; K Staufer; Petra Steindl-Munda; F Wrba; I Aydin; Peter Ferenci
Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.
Journal of viral hepatitis 2011;18(7):513-7.
2011: Thomas-Matthias Scherzer; Harald Hofer; Albert Friedrich Staettermayer; Karoline Rutter; Sandra Beinhardt; Petra Steindl-Munda; Heidrun Kerschner; Harald H Kessler; Peter Ferenci
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
Journal of hepatology 2011;54(5):866-71.
2011: Albert Friedrich Stättermayer; Rudolf Stauber; Harald Hofer; Karoline Rutter; Sandra Beinhardt; Thomas Matthias Scherzer; Kerstin Zinober; Christian Datz; Andreas Maieron; Emina Dulic-Lakovic; Harald H Kessler; Petra Steindl-Munda; Michael Strasser; Christoph Krall; Peter Ferenci
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011;9(4):344-350.e2.
2010: Benjamin Vyssoki; Petra Steindl-Munda; Peter Ferenci; Henriette Walter; Peter Höfer; Victor Blüml; Fabian Friedrich; Dagmar Kogoj; Otto M Lesch
Comparison of alcohol-dependent patients at a gastroenterological and a psychiatric ward according to the Lesch alcoholism typology: implications for treatment.
Alcohol and alcoholism (Oxford, Oxfordshire) 2010;45(6):534-40.
2010: Martin Krssák; Harald Hofer; Fritz Wrba; Martin Meyerspeer; Attila Brehm; Alfred Lohninger; Petra Steindl-Munda; Ewald Moser; Peter Ferenci; Michael Roden
Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy.
European journal of radiology 2010;74(3):e60-6.
2010: Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Andreas Maieron; Harald Hofer; Rudolf Stauber; Michael Gschwantler; Harald Brunner; Christoph Wenisch; Martin Bischof; Michael Strasser; Christian Datz; Wolfgang Vogel; Karin Löschenberger; Petra Steindl-Munda
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Gastroenterology 2010;138(2):503-12, 512.e1.
2008: Peter Ferenci; Thomas-Matthias Scherzer; Heidrun Kerschner; Karoline Rutter; Sandra Beinhardt; Harald Hofer; Maximilian Schöniger-Hekele; Heidemarie Holzmann; Petra Steindl-Munda
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
Gastroenterology 2008;135(5):1561-7.
2008: T M Scherzer; K Staufer; Gottfried Novacek; Petra Steindl-Munda; S Schumacher; Harald Hofer; Peter Ferenci; Harald Vogelsang
Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.
Alimentary pharmacology & therapeutics 2008;28(6):742-8.
2008: T-M Scherzer; K Rajender Reddy; F Wrba; Harald Hofer; K Staufer; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci
Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C.
Journal of viral hepatitis 2008;15(9):659-65.
2008: Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Michael Gschwantler; Andreas Maieron; Harald Brunner; Rudolf E Stauber; Martin Bischof; Bernhard Bauer; Christian Datz; Karin Löschenberger; Elisabeth Formann; Katharina Staufer; Petra Steindl-Munda
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Gastroenterology 2008;135(2):451-8.
2008: Peter Ferenci; Harald Brunner; Hermann Laferl; Thomas-Matthias Scherzer; Andreas Maieron; Michael Strasser; Gabriele Fischer; Harald Hofer; Martin Bischof; Rudolf E Stauber; Michael Gschwantler; Petra Steindl-Munda; Katharina Staufer; Karin Löschenberger
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Hepatology (Baltimore, Md.) 2008;47(6):1816-23.
2008: Lili Kazemi-Shirazi; Moema Pinheiro Veloso; Florian Frommlet; Petra Steindl-Munda; Fritz Wrba; Sonja Zehetmayer; Claudia Marsik; Peter Ferenci
Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful?
Wiener klinische Wochenschrift 2008;120(1-2):25-30.
2007: Judith H Aberle; Gabriela Perstinger; Lukas Weseslindtner; Ursula Sinzinger; Calin Gurguta; Petra Steindl-Munda; Michael Kundi; Theresia Popow-Kraupp; Peter Ferenci; Heidemarie Holzmann
CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance.
The Journal of infectious diseases 2007;195(9):1315-9.
2007: Arnulf Ferlitsch; Petra Steindl-Munda; Michael Haefner; Markus Peck-Radosavljevic; Christian Madl; Regina Pötzi; Monika Homoncik; Claudia Weidekamm; Susanne Granegger; Helmut Sinzinger
Prescintigraphic morphine application for abdominal adenocarcinoma imaging, with technetium-99m methoxy isobutyl isonitrile.
Hellenic journal of nuclear medicine 2007;10(1):14-8.
2006: Harald Hofer; Calin Gurguta; Ulrike Bergholz; Petra Steindl-Munda; Peter Ferenci
Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
Wiener klinische Wochenschrift 2006;118(19-20):595-600.
2006: Judith H Aberle; Elisabeth Formann; Petra Steindl-Munda; Lukas Weseslindtner; Calin Gurguta; Gabriela Perstinger; Evelyn Grilnberger; Hermann Laferl; Hans P Dienes; Theresia Popow-Kraupp; Peter Ferenci; Heidemarie Holzmann
Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2006;36(1):24-31.
2006: Elisabeth Formann; Petra Steindl-Munda; Harald Hofer; Wolfgang Jessner; Ulrike Bergholz; Calin Gurguta; Peter Ferenci
Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
Alimentary pharmacology & therapeutics 2006;23(4):507-11.
2006: Peter Ferenci; Elisabeth Formann; Hermann Laferl; Michael Gschwantler; Franz Hackl; Harald Brunner; Rainer Hubmann; Christian Datz; Rudolf E Stauber; Petra Steindl-Munda; Harald H Kessler; Anton Klingler; Alfred Gangl
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Journal of hepatology 2006;44(2):275-82.
2006: Calin Gurguta; Clemens Kauer; Ulrike Bergholz; Elisabeth Formann; Petra Steindl-Munda; Peter Ferenci
Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.
The American journal of gastroenterology 2006;101(1):197-8.
2005: Ludwig Kramer; Harald Hofer; Edith Bauer; Georg Funk; Elisabeth Formann; Petra Steindl-Munda; Peter Ferenci
Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection.
AIDS (London, England) 2005;19 Suppl 3():S85-92.
2005: Peter Ferenci; Petra Steindl-Munda; Wolfgang Vogel; Wolfgang Jessner; Michael Gschwantler; Rudolf E Stauber; Christian Datz; Franz Hackl; Fritz Wrba; Peter Bauer; Oskar Lorenz
Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2005;3(8):811-8.
2004: Thomas Watkins-Riedel; Peter Ferenci; Petra Steindl-Munda; Michael Gschwantler; Christian Mueller; Markus Woegerbauer
Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(12):1754-60.
2004: Rudolf E Stauber; Harald Hofer; Franz Hackl; Kurt Schütze; Christian Datz; Karin Hegenbarth; Wolfgang Jessner; Petra Steindl-Munda; Ferenci Peter
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Wiener klinische Wochenschrift 2004;116(15-16):530-5.
2004: Harald Hofer; Christoph H Osterreicher; Wolfgang Jessner; Melitta Penz; Petra Steindl-Munda; Fritz Wrba; Peter Ferenci
Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Journal of hepatology 2004;40(6):1018-22.
2003: Petra Steindl-Munda; Peter Ferenci; Harald Brunner; Karin Nachbaur; Christian Datz; Michael Gschwantler; Harald Hofer; Rudolf E Stauber; Franz Hackl; Wolfgang Jessner; Martha Rosenbeiger; Alfred Gangl; Wolfgang Vogel
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Liver international : official journal of the International Association for the Study of the Liver 2003;23(4):269-75.
2003: Harald Hofer; Thomas Watkins-Riedel; Oskar Janata; Edward Penner; Heidemarie Holzmann; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.
Hepatology (Baltimore, Md.) 2003;37(1):60-4.
2002: Wolfgang Jessner; Thomas Watkins-Riedel; Elisabeth Formann; Petra Steindl-Munda; Peter Ferenci
Hepatitis C viral dynamics: basic concept and clinical significance.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2002;25 Suppl 3():S31-9.
2002: Harald Hofer; Hans C Bankl; Fritz Wrba; Petra Steindl-Munda; Markus Peck-Radosavljevic; Christoph H Osterreicher; Christian Mueller; Alfred Gangl; Peter Ferenci
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.
The American journal of gastroenterology 2002;97(11):2880-5.
2002: Wolfgang Jessner; Manon Der-Petrossian; Lene Christiansen; Harald Maier; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci
Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C.
Hepatology (Baltimore, Md.) 2002;36(5):1301-2.
2002: Ludwig Kramer; Edith Bauer; Georg Funk; Harald Hofer; Wolfgang Jessner; Petra Steindl-Munda; Fritz Wrba; Christian Madl; Alfred Gangl; Peter Ferenci
Subclinical impairment of brain function in chronic hepatitis C infection.
Journal of hepatology 2002;37(3):349-54.
2002: Gerald Mundigler; Georg Delle-Karth; Maria Koreny; Manfred Zehetgruber; Petra Steindl-Munda; Wolfgang Marktl; Lisa Ferti; Peter Siostrzonek
Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis.
Critical care medicine 2002;30(3):536-40.
2001: Wolfgang Jessner; Michael Gschwantler; Petra Steindl-Munda; H Hofer; Thomas Watkins-Riedel; F Wrba; C Mueller; A Gangl; P Ferenci
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.
Lancet 2001;358(9289):1241-2.
2001: Peter Ferenci; Rudolf E Stauber; Petra Steindl-Munda; Michael Gschwantler; Peter Fickert; Christian Datz; Christian Müller; Franz Hackl; W Rainer; Thomas Watkins-Riedel; W Lin; Günter J Krejs; Alfred Gangl
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
European journal of gastroenterology & hepatology 2001;13(6):699-705.
1999: Peter Ferenci; Rudolf E Stauber; Petra Steindl-Munda; Michael Gschwantler; Peter Fickert; Christian Datz; Christian Müller; Franz Hackl; W Rainer; Thomas Watkins-Riedel; W Lin
Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.
Journal of viral hepatitis 1999;6 Suppl 1():53-8.